- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
News
Article
SLIDESHOW: Overview of July 2024 FDA Approvals
Author(s):
Take a deep dive into the 3 approvals for various dermatological conditions this month.
This month, the US Food and Drug Administration approved 3 different treatment options, giving patients with plaque psoriasis, psoriatic arthritis, pediatric atopic dermatitis, and alopecia more options for treatment.
Explore the clinical trial data leading up to these approvals, and don't miss a moment of approval news—subscribe to our email newsletters.
References
1. Andrus A. FDA approves biosimilar ustekinumab-ttwe for all indications of reference medicine. Dermatology Times. July 1, 2024. Accessed July 30, 2024. https://www.dermatologytimes.com/view/fda-approves-biosimilar-ustekinumab-ttwe-for-all-indications-of-reference-medicine
2. Bader K. FDA approves roflumilast cream 0.15% for atopic dermatitis in patients aged 6 years and older. Dermatology Times. July 9, 2024. Accessed July 30, 2024. https://www.dermatologytimes.com/view/fda-approves-roflumilast-cream-0-15-for-atopic-dermatitis-in-patients-aged-6-years-and-older
3. Buchanan L. The FDA approves deuruxolitinib for severe alopecia in adults. Dermatology Times. July 26, 2024. Accessed July 30, 2024. https://www.dermatologytimes.com/view/the-fda-approves-deuruxolitinib-for-severe-alopecia-in-adults
